Figure 1
Blood samples for evaluation of MGCD0103 pharmacokinetics. Samples were collected during cycle 1 on day 1 and day 12 before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after dose. Samples were analyzed using a validated HPLC/MS method. Dosing of MGCD0103 was 2 times per week. (A,B) Plasma concentration-time profiles for day 1; n = 27 patients. (C,D) Plasma concentration-time profiles for day 12; n = 13 patients.

Blood samples for evaluation of MGCD0103 pharmacokinetics. Samples were collected during cycle 1 on day 1 and day 12 before dosing and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after dose. Samples were analyzed using a validated HPLC/MS method. Dosing of MGCD0103 was 2 times per week. (A,B) Plasma concentration-time profiles for day 1; n = 27 patients. (C,D) Plasma concentration-time profiles for day 12; n = 13 patients.

Close Modal

or Create an Account

Close Modal
Close Modal